Third Harmonic Bio . Thu, Jun 12, 2025, 8:00 AM 5 min read. In This Article: THRD . Stockholders overwhelmingly approved liquidation and dissolution of the Company. at the June 5, 2025 Annual Meeting.

Third Harmonic Bio has completed clinical, toxicology and manufacturing activities to support a Phase 2 clinical trial of THB335 for chronic spontaneous urticaria.

SAN FRANCISCO - Third Harmonic Bio, Inc. (NASDAQ:THRD), a biotech company with a market capitalization of $237.37 million and notably strong liquidity position, has received stockholder approval for ...

(RTTNews) - Third Harmonic Bio, Inc. (THRD) on Thursday announced that its stockholders overwhelmingly approved the company's proposed Plan of Liquidation and Dissolution at its Annual Meeting ...

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed cashed in on a stock surge and Third Harmonic kicked off a drug auction.

SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD) today announced that its stockholders overwhelmingly approved the previously proposed Plan of Liquidation and ...

Third Harmonic Bio Announces Stockholder Approval Of Plan Of Liquidation And Dissolution, Updated THB335 Phase 1 Clinical Data, And Initiation Of Sale Of THB335. Date. 2025-06-12 08:16:19.

Learn about the executive team and board of directors at Third Harmonic Bio Inc (THRD:XNAS) and review their bios and compensation over the latest fiscal years.

Third Harmonic Bio Announces Third Quarter 2024 Financial Results GlobeNewswire Thu, Nov. 07, 2024 Third Harmonic Bio to Participate in Upcoming Investor Conferences in September ...

Review Third Harmonic Bio Inc (THRD:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Get the annual and quarterly balance sheet of Third Harmonic Bio, Inc. (THRD) including details of assets, liabilities and shareholders' equity.